
Şrife Gül KaradaÄŸ

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3943053/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study. Rheumatology International, 2022, 42, 879-889.	3.0	35
2	Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19. Rheumatology International, 2020, 40, 1613-1623.	3.0	32
3	The clinical spectrum of Henoch–Schönlein purpura in children: a single-center study. Clinical Rheumatology, 2019, 38, 1707-1714.	2.2	30
4	Comorbidities and phenotype–genotype correlation in children with familial Mediterranean fever. Rheumatology International, 2021, 41, 113-120.	3.0	30
5	Real-Life Data From the Largest Pediatric Familial Mediterranean Fever Cohort. Frontiers in Pediatrics, 2021, 9, 805919.	1.9	22
6	Characteristics of pediatric Behçet's disease in Turkey and Israel: A cross-sectional cohort comparison. Seminars in Arthritis and Rheumatism, 2020, 50, 515-520.	3.4	18
7	Subtype frequencies, demographic features, and remission rates in juvenile idiopathic arthritis - 265 cases from a Turkish center. Turkish Journal of Pediatrics, 2017, 59, 548-554.	0.6	18
8	Performance of Tel-Hashomer, Livneh, pediatric and new Eurofever/PRINTO classification criteria for familial Mediterranean fever in a referral center. Rheumatology International, 2020, 40, 21-27.	3.0	17
9	ADA2 Deficiency: Case Series of Five Patients with Varying Phenotypes. Journal of Clinical Immunology, 2020, 40, 253-258.	3.8	17
10	Leflunomide treatment in juvenile idiopathic arthritis. Rheumatology International, 2019, 39, 1615-1619.	3.0	16
11	The relevance of practical laboratory markers in predicting gastrointestinal and renal involvement in children with Henoch–Schönlein Purpura. Postgraduate Medicine, 2021, 133, 272-277.	2.0	16
12	Etiologic Spectrum and Follow-Up Results of Noninfectious Uveitis in Children: A Single Referral Center Experience. Archives of Rheumatology, 2019, 34, 294-300.	0.9	15
13	The frequency of macrophage activation syndrome and disease course in systemic juvenile idiopathic arthritis. Modern Rheumatology, 2020, 30, 900-904.	1.8	12
14	Age of onset as an influencing factor for disease severity in children with familial Mediterranean fever. Modern Rheumatology, 2021, 31, 219-222.	1.8	12
15	Canakinumab in colchicine resistant familial mediterranean fever and other pediatric rheumatic diseases. Turkish Journal of Pediatrics, 2020, 62, 167.	0.6	10
16	Profile of new referrals to a single pediatric rheumatology center in Turkey. Rheumatology International, 2020, 40, 313-321.	3.0	9
17	Genetic panel screening in patients with clinically unclassified systemic autoinflammatory diseases. Clinical Rheumatology, 2020, 39, 3733-3745.	2.2	9
18	Comparison of the clinical diagnostic criteria and the results of the next-generation sequence gene panel in patients with monogenic systemic autoinflammatory diseases. Clinical Rheumatology, 2021, 40, 2327-2337.	2.2	9

#	Article	IF	CITATIONS
19	The Value of Serum Amyloid A Levels in Familial Mediterranean Fever to Identify Occult Inflammation During Asymptomatic Periods. Journal of Clinical Rheumatology, 2021, 27, 1-4.	0.9	9
20	Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus, 2021, 30, 2144-2150.	1.6	9
21	Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study. Rheumatology International, 2020, 40, 1111-1116.	3.0	8
22	Rheumatic diseases in Syrian refugee children: a retrospective multicentric study in Turkey. Rheumatology International, 2020, 40, 583-589.	3.0	7
23	Comparison of Pediatric Familial Mediterranean Fever Patients Carrying Only E148Q Variant With the Ones Carrying Homozygous Pathogenic Mutations. Journal of Clinical Rheumatology, 2021, 27, 182-186.	0.9	7
24	Clinical experiences in turkish paediatric patients with chronic recurrent multifocal osteomyelitis. Turkish Journal of Pediatrics, 2019, 61, 879.	0.6	7
25	Serum amyloid A as a biomarker in differentiating attacks of familial Mediterranean fever from acute febrile infections. Clinical Rheumatology, 2020, 39, 249-253.	2.2	6
26	Two cases of periodic fever syndrome with coexistent mevalonate kinase and Mediterranean fever gene mutations. Turkish Journal of Pediatrics, 2017, 59, 467-470.	0.6	6
27	Time to collaborate: Objectives, Design, and Methodology of PeRA-Research Group. İstanbul Kuzey Klinikleri, 2020, 8, 200-202.	0.3	6
28	Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center. Rheumatology International, 2020, 40, 771-776.	3.0	5
29	Isotretinoinâ€induced sacroiliitis: Case series of four patients and a systematic review of the literature. Pediatric Dermatology, 2020, 37, 171-175.	0.9	5
30	Atypical phenotype of an old disease or typical phenotype of a new disease: deficiency of adenosine deaminase 2. Turkish Journal of Pediatrics, 2019, 61, 413.	0.6	5
31	Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group. Expert Opinion on Biological Therapy, 2022, 22, 197-202.	3.1	5
32	The influence of carrying MEFV gene variants on juvenile systemic lupus erythematosus. Rheumatology International, 2021, 41, 157-161.	3.0	4
33	Adherence to best practice consensus guidelines for familial Mediterranean fever: a modified Delphi study among paediatric rheumatologists in Turkey. Rheumatology International, 2021, , 1.	3.0	4
34	Complete and sustained resolution of calcinosis universalis in a juvenile dermatomyositis case with mycophenolate mofetil. Turkish Journal of Pediatrics, 2019, 61, 771.	0.6	4
35	Why is the frequency of uveitis low in Turkish children with juvenile idiopathic arthritis?. Rheumatology, 2019, 59, 679-680.	1.9	2
36	The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis. İstanbul Kuzey Klinikleri, 2019, 7, 118-123.	0.3	2

Şerife Gül KaradaÄŸ

#	Article	IF	CITATIONS
37	Is it all about age? Clinical characteristics of Kawasaki disease in the extremely young: PeRA research group experience. Postgraduate Medicine, 2022, 134, 429-434.	2.0	2
38	Differential diagnosis portfolio of a pediatric rheumatologist: eight cases, eight stories. Clinical Rheumatology, 2021, 40, 769-774.	2.2	1
39	Hepatitis B vaccination response of treatment-naive patients with juvenile idiopathic arthritis. Rheumatology International, 2021, , 1.	3.0	1
40	Coexistence of Juvenile Systemic Lupus Erythematosus and Juvenile Spondyloarthropathy: A Case Report and Review of the Literature. Archives of Rheumatology, 2020, 35, 132-136.	0.9	0
41	Response to â€~How to define disease severity accurately in patients with familial Mediterranean fever'. Rheumatology International, 2021, 41, 239-240.	3.0	0
42	We might have the same mutation but my inflammasome beats your inflammasome: CINCA versus FCAS. ReumatologÃa ClÃnica, 2021, 17, 118-119.	0.5	0
43	An extreme entity in differential diagnosis of musculoskeletal involvement-fibrodysplasia ossificans progressiva: a case based review. Turkish Journal of Pediatrics, 2018, 60, 593.	0.6	0